Abstract
Background: The comparison of molecular genetic changes in healthy and pathological tissues has historically led to the identification of oncogenes and tumor suppressor genes. It is very common that studies investigating loss of heterozygosity are carried out retrospectively on paraffin-embedded samples.
Methods: In this study, we evaluated the power of pyrosequencing for determining the loss of heterozygotic regions. The present method uses the fact that pyrosequencing is an accurate, sensitive and reproducible technique. The method is also simple to perform, with results available in 96-well format, making the assays amenable to automation. Thus, we analyzed nine single nucleotide polymorphisms along 1Mb between the EMSY and PAK1 genes on 11q13, a region frequently rearranged in different tumors and cell lines. We assessed the study using samples from breast cancer and thyroid cancer biopsies.
Results and conclusions: We conclude that this technique is capable of detecting variations of >10% in allele loss. However, strong allele imbalances were detected, depending on the origin of the sample. Seven out of the nine markers used exhibited differential allele amplification, depending on the DNA quality (p<0.01).
Clin Chem Lab Med 2006;44:1076–81.
References
1. Kinzler KW, Vogelstein B. The genetic basis of human cancer, 2nd ed. Toronto: McGraw-Hill, 2002.Search in Google Scholar
2. Onyango P. Genomics and cancer. Curr Opin Oncol 2002; 14:79–85.10.1097/00001622-200201000-00014Search in Google Scholar
3. Shih IM, Wang TL. Apply innovative technologies to explore cancer genome. Curr Opin Oncol 2004; 17:33–8.Search in Google Scholar
4. Zhou X, Li C, Mok S, Chen Z, Wong DT. Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genet Cytogenet 2004; 151:82–4.10.1016/j.cancergencyto.2003.11.010Search in Google Scholar
5. Kennedy GC, Matsuzaki H, Dong S, Liu WM, Huang J, Liu G, et al. Large-scale genotyping of complex DNA. Nat Biotechnol 2003; 21:1233–7.10.1038/nbt869Search in Google Scholar
6. Zhou X, Rao NP, Cole SW, Mok SC, Chen Z, Wong DT. Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. Cancer Genet Cytogenet 2005; 159:53–7.10.1016/j.cancergencyto.2004.09.014Search in Google Scholar
7. Zhou X, Mok SC, Chen Z, Li Y, Wong DT. Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 2004; 115:327–30.10.1007/s00439-004-1163-1Search in Google Scholar
8. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphatase. Science 1998; 281:363–5.10.1126/science.281.5375.363Search in Google Scholar
9. Ahmadian A, Gharizadeh B, Gustafsson AC, Sterky F, Nyren P, Uhlen M, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem 2000; 280:103–10.10.1006/abio.2000.4493Search in Google Scholar
10. Van Goethem G, Dermaut B, Löfgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28:211–2.10.1038/90034Search in Google Scholar
11. Ahmadian A, Lundeberg J, Nyren P, Uhlen M, Ronaghi M. Analysis of the p53 tumor suppressor gene by pyrosequencing. Biotechniques 2000; 28:140–7.10.2144/00281rr02Search in Google Scholar
12. Garcia CA, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyren P. Mutation detection by pyrosequencing: sequencing of exons 5–8 of the p53 tumor suppressor gene. Gene 2000; 253:249–57.10.1016/S0378-1119(00)00257-2Search in Google Scholar
13. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, et al. Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinoma. Cytogenet Cell Genet 1997; 79:125–31.10.1159/000134699Search in Google Scholar
14. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115:523–35.10.1016/S0092-8674(03)00930-9Search in Google Scholar
15. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5–q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003; 163:985–92.10.1016/S0002-9440(10)63458-XSearch in Google Scholar
16. Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93:1141–6.10.1093/jnci/93.15.1141Search in Google Scholar PubMed
17. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003; 198:1381–9.10.1084/jem.20030580Search in Google Scholar PubMed PubMed Central
18. Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 2004; 10:5785–91.10.1158/1078-0432.CCR-03-0410Search in Google Scholar PubMed
19. King MC. A novel BRCA2-binding protein and breast and ovarian tumorigenesis. N Engl J Med 2004; 350:1252–3.10.1056/NEJMcibr033528Search in Google Scholar PubMed
20. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258:818–21.10.1126/science.1359641Search in Google Scholar PubMed
21. Ylstra B, van den Ijssel P, Carvalho B, Brakenhoff RH, Meijer GA. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res 2006; 34:445–50.10.1093/nar/gkj456Search in Google Scholar PubMed PubMed Central
©2006 by Walter de Gruyter Berlin New York
